Key points: - They went over the recent presentation - Jublia: many competitors applied for generics but Acrux were one of few that got it approved. All competitors challenged the patents and there was a confidential settlement with Valeant. This settlement included when it can be launched but they are unable to disclose the date otherwise they will be breaking the terms of the settlement. The market share by is estimated at 400m by IQVIA but Acrux thinks that is overstated as the last time Jublia sales were reported was in 2020 and it was around 100m. But still, its a very good market as the price of Jublia is extremely high so i am guessing the margins would be high.
- Prilocaine / Lidocaine Cream: the API increase is a good guide to the expected sales......so I expect material upside this year. They seem very bullish on this and they stated the market is underserved.
Overall, a very positive sentiment.
ACR Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
